Metabolic processes underlying the development of the neural crest, an embryonic population of multipotent migratory cells, are poorly understood. Here, we report that conditional ablation of the Lkb1 tumor suppressor kinase in mouse neural crest stem cells led to intestinal pseudo-obstruction and hind limb paralysis. This phenotype originated from a postnatal degeneration of the enteric nervous ganglia and from a defective differentiation of Schwann cells. Metabolomic profiling revealed that pyruvate-alanine conversion is enhanced in the absence of Lkb1. Mechanistically, inhibition of alanine transaminases restored glial differentiation in an mTOR-dependent manner, while increased alanine level directly inhibited the glial commitment of neural crest cells. Treatment with the metabolic modulator AICAR suppressed mTOR signaling and prevented Schwann cell and enteric defects of Lkb1 mutant mice. These data uncover a link between pyruvate-alanine cycling and the specification of glial cell fate with potential implications in the understanding of the molecular pathogenesis of neural crest diseases.
INTRODUCTION
Neural crest cells (NCCs) are highly invasive stem cells that originate from the dorsolateral folds of the neural tube and delaminate from the neuroepithelium through an epithelial-mesenchymal transition (1) . NCCs migrate along stereotypical paths and give rise to a broad array of derivatives including most of the craniofacial skeleton, neuroendocrine tissues, and pigment cells. Furthermore, the peripheral nervous system, comprising sensory neurons and Schwann cells of the parasympathetic and sympathetic nervous systems, as well as neurons and glial cells that constitute the enteric nervous system, arises from NCCs. Defects in human neural crest development are the cause of a constellation of disorders called neurocristopathies. The most common clinical phenotypes include craniofacial abnormalities, hearing loss, absence of pigmentation, cardiac defects, and enteric ganglia agenesis (2) . Although the cascade of molecular events that specify neural crest territories, orchestrate NCC delamination, and guide their polarized migration throughout the embryo has been extensively explored, the contribution of metabolic regulation to NCC formation and differentiation has received less attention. In this regard, morphogenesis requires adjustment of the metabolism of embryonic cells to cope with alterations in nutrient availability and tissue oxygenation specific to their microenvironment (3) . The mapping of the metabolic pathways that are activated in early stem cells has begun to shed light on the respective contribution of glycolysis versus oxidative phosphorylation in the maintenance of pluripotency and cell fate commitment (4) . However, the role of metabolic remodeling in later developmental stages, including the formation of neural crest derivatives, remains poorly understood.
The tumor suppressor liver kinase B1 (LKB1; also named STK11) encodes a serine/threonine kinase that has been evolutionarily conserved from invertebrates to mammals (5, 6) . Germline mutations of LKB1 are responsible for the Peutz-Jeghers syndrome, a dominantly inherited cancer disorder, and somatic mutations of this gene have been associated with various cancers including lung and cervical tumors (7) . The binding of LKB1 to the pseudokinase STRAD (STRAD or STRAD) and the scaffolding molecule MO25 allosterically controls LKB1 catalytic activity and promotes its nuclear export (8) . LKB1 acts as a key regulator of energy metabolism through the activation of the AMP (adenosine 5′-monophosphate)-activated protein kinase (AMPK), a sensor that adapts energy supply to the nutrient demands of cells facing situations of metabolic stress (9) . AMPK phosphorylates a large array of substrates to achieve metabolic adaptation. In particular, AMPK phosphorylates the acetyl CoA (coenzyme A) carboxylase (ACC) to inhibit fatty acid synthesis (10, 11) as well as two regulators of mammalian target of rapamycin complex 1 (mTORC1), RAPTOR and TSC2, to inhibit the mTOR pathway (12, 13) . In addition to AMPK, LKB1 also phosphorylates 12 AMPK-related kinases that regulate cell polarization, axon branching of cortical neurons, and hepatic neoglucogenesis (14) (15) (16) (17) .
We recently showed that Lkb1 governs delamination, migration, differentiation, and survival of cephalic NCC, these complex morphogenetic processes being essential for vertebrate head formation (18) . To further understand the contribution of Lkb1 to the establishment of neural crest lineages, we disrupted this gene in a subset of vagal and truncal mouse NCC using the tyrosinase Cre (Tyr::Cre) transgene.
Lkb1 expression (Fig. 2A) . The loss of Lkb1 did not impair melanoblast migration at E15.5 ( Fig. 2B ) but led to a drastic reduction of melaninproducing melanocytes in the hair follicles, as visualized by immunostaining of the melanin biosynthesis enzyme dopachrome tautomerase ( Fig. 2C ) and hematoxylin and eosin staining ( fig. S2C ).
Lkb1 inactivation causes enteric nervous system degeneration
We next explored the pathophysiological defects that lead to the intestinal pseudo-obstruction. By immunohistochemistry, Lkb1 expression was observed in myenteric and submucosal plexuses in both the intestine and colon of P6 and P21 mice (Fig. 2D and fig. S3 , A and B). The anti-Lkb1 antibody identified enteric ganglia because the labeling colocalized with the neuron-specific III-tubulin Tuj1 marker ( fig. S3C ). As expected, little or no Lkb1 was detected in the ganglia of cKO mice. Confocal analysis of -Gal expression as the Cre reporter together with neural-specific (HuC/D) and glial-specific [glial fibrillary acidic protein (GFAP)] markers revealed staining in both neural and glial enteric cells ( fig. S3D) . A similar LKB1 expression pattern was observed in human intestine and colon specimens ( fig. S3E ). Together, these results indicate that Lkb1 is expressed in human and mouse enteric cells and that Lkb1 inactivation occurred in neural and glial enteric cells.
To determine whether the enteric nervous system was affected in cKO mice, whole-mount staining of enteric neurons with the neural marker Tuj1 was performed at E15.5 ( fig. S3F ) and at birth (Fig. 2E) . No overt sign of alteration of the enteric nervous system network was observed at both stages. However, at P6, cKO animals exhibited a clear reduction of the numbers of neural (Tuj1)-and glial (GFAP)-positive ganglia in the distal intestine and colon. The remaining ganglia were smaller in size and displayed punctiform morphology ( fig. S3G ). To visualize the enteric network at P21, acetylcholine esterase (AChE) staining was used. Although the neuronal network was clearly visible in the WT intestine, the staining was strongly diminished in Lkb1-deficient mice (Fig. 2F) , as illustrated by the reduced percentage of surface covered by the cholinergic network ( fig. S3H ). The tunica muscularis and enterocyte epithelium had normal morphology. However, reduced size of intestinal villi in the distal intestine, probably due to fecal accumulation in the digestive tract, was frequently observed ( fig. S3I ). -Gal expression on whole-mount intestine at P21 stained the enteric network in WT animals, whereas the enteric nervous system of cKO animals showed a drastic decrease of labeling ( fig. S3J ). These results were confirmed by measuring ganglia surfaces in relation to the length of tunica muscularis ( fig. S3K ). We also showed that global neural (Tuj1) staining was decreased in the absence of Lkb1, especially in ganglia inactivated for Lkb1 (Fig. 2G and fig. S3L ). Similarly, glial cell number was reduced upon Lkb1 loss, as visualized with GFAP staining on intestine and colon sections of P21 mice ( fig. S3M ). The most frequently hypoganglionic area was the distal intestine, while the proximal colon was not affected (fig. S3N ). The number of enteric neurons per length of tunica muscularis was 2-fold lower in the distal intestine of cKO animals and 1.6-fold lower in the distal colon as compared to WT controls (Fig. 2H) . No sign of apoptosis was detected in enteric ganglia of cKO animals, neither with the TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay at P21 nor with the cleaved caspase-3 immunostaining at P6 (fig. S3O ). These results show that Lkb1 deficiency is associated with a progressive postnatal degeneration, leading to an enteric hypoganglionosis.
Lkb1 inactivation triggers a peripheral neuropathy
Lkb1 expression was detected on sciatic nerve sections at P6 and P21 ( Fig. 2I and fig. S4A ). A homogeneous staining of Lkb1 was observed in WT animals, while in cKO mice, Lkb1 staining was reduced. We next examined whether Lkb1 was inactivated at embryonic stages in peripheral sensory axons, in glial cells, or in both by exploiting the Tyr::Cre;Z/EG mice (28) . Labeling of neural crest-derived cells expressing the Cre recombinase, together with enhanced green fluorescent protein (EGFP), showed that glial GFAP-positive cells were also positive for EGFP ( fig. S4B ), whereas Tuj1-positive neurons were not positive for EGFP ( fig. S4C ). We also took advantage of the presence of the R26R reporter to stain semithin sections of sciatic nerves with X-Gal. These studies revealed labeling of Schwann cells but not of axons ( fig. S4D) . A sustained -Gal activity was also detected in the dorsal root ganglia of either WT or cKO animals using Salmon Gal, another substrate of the -Gal ( fig. S4E ). Immunofluorescence analyses of -Gal expression in dorsal root ganglia demonstrated a clear colocalization with glial GFAP-positive cells but not with neuronal Tuj1-positive cells ( fig. S4F ). Together, these results indicate that Lkb1 inactivation was restricted to glial cells and did not occur in sensory neurons.
We next examined the ultrastructure of sciatic nerves at P21 by transmission electron microscopy. Sciatic nerves of control animals were composed of myelinated sensory and motor axons of medium to large diameters and clusters of small-diameter unmyelinated sensory axons (Fig. 2J, a and b) . Large clusters of unsorted axons were identified (Fig. 2J, c and d) . Nonmyelinating Schwann cells of cKO mice did not enwrap axons individually as in WT animals but wrapped axons in bulk (Fig. 2J, b and d) . Several axons achieved an appropriate 1:1 relationship with Schwann cells, but others showed aberrant sorting or remained unsorted (Fig. 2J, e and f) . To quantify axon myelination defects in cKO animals, we measured the g ratio, the ratio of the axonal diameter to the myelinated fiber diameter. An increased g ratio was quantified in mutant mice (Fig. 2K) , indicating hypomyelination of axons in cKO animals. The number of myelinated axons was reduced, and the degeneration of axons was also observed ( fig. S4 , G, and H). Along this line, neural Tuj1 staining was strongly reduced at both P6 and P21 (Fig. 2L and fig. S4I ). As described previously (26, 27) , we also observed Schwann cell polarity defects using GFAP and E-cadherin staining (fig. S4, J and K). Together, these results yielded evidence that Lkb1 is required for the proper differentiation of Schwann cells.
Lkb1 controls glial fate specification
To explore the molecular mechanisms underlying these phenotypic defects, we first assessed the activation of AMPK by immunohistochemistry. Although total AMPK staining was not different between WT and cKO enteric ganglia ( fig. S5A) , AMPK phosphorylation at the LKB1 target residue, AMPK Thr172 , was specifically decreased in the enteric ganglia of cKO mice, whereas no changes were seen in smooth muscle cell layers or enterocytes (Fig. 3A) . In addition, an accumulation of Sox2-positive cells (Fig. 3B) , which correspond to enteric progenitors and glial cells (29) , was observed in the plexus ganglia of cKO mice, albeit no increase of glial cell number was detected ( fig. S3M ). We also observed an increase of enteric progenitors defined as cells expressing the low-affinity neurotrophin receptor p75 NTR (30, 31) but not the neural marker Tuj1 (fig. S5B ). Together, these data indicate that Lkb1 deficiency is responsible for the lack of enteric progenitor differentiation.
Similarly, phospho-AMPK staining was markedly decreased in the absence of Lkb1 on longitudinal sections of sciatic nerves (Fig. 3C) , although there was no difference in total AMPK staining on sciatic nerves of WT and cKO animals ( fig. S5C ). While studying transverse and longitudinal sections of cKO sciatic nerves, an increased number of nuclei were observed at P6 and P21 (Fig. 3D) . To assess the identity of these cells, we labeled immature/promyelinating Schwann cells with Sox2 (32) . A net increase of Sox2-positive cells was observed in cKO mice at P6, and this was also evident, although at a lower extent at P21 (Fig. 3E ). Similar results were obtained using p75
NTR as a marker of Schwann cell progenitors (33) . In WT animals, p75
NTR -positive Schwann cells were mainly observed in association with axons and likely correspond to mature Schwann cells. In cKO animals, we quantified a threefold increase of p75 NTR -positive progenitor cells not associated with axons ( fig. S5D ). These data were also confirmed using an antibody that recognizes Krox20, a transcription factor that is a pivotal regulator of Schwann cell myelination ( Fig. 3F ). At P6, only a small fraction of Krox20-positive nuclei were detected in cKO animals, thus confirming that, in the absence of Lkb1, the differentiation of Schwann cell is delayed.
To examine the consequences of Lkb1 inactivation on NCC fate at early stages of glial differentiation, we used the JoMa1.3 mouse neural crest stem cell line, which can be either maintained in a progenitor state or differentiated into glial cells ( S6J ). Expression of glial specific marker S100 or GFAP (Fig. 3I ) was also reduced, and p75 NTR RNA expression was increased upon Lkb1 knockdown (Fig. 3J ). In addition, Lkb1 loss did not trigger any neural differentiation ( fig. S6K ), thus confirming that these cells were maintained in a progenitor state. Collectively, our results provide evidence that Lkb1 is key to commit NCC-derived cells toward a glial cell fate.
Rewiring of metabolism in Lkb1-deficient nerves
To examine the metabolic changes induced upon Lkb1 ablation in NCC derivatives, we investigated the metabolic status of sciatic nerves because they are the most NCC-enriched tissue compared to enteric nervous system and skin and it is the easiest structure to dissect out. We performed high-resolution magic angle spinning (HRMAS) proton nuclear magnetic resonance (NMR) spectroscopy, a technique that does not require previous solubilization of the samples. By applying this technique to structurally preserved nerves, the variations in both polar metabolite and lipid levels in Lkb1 cKO sciatic were recorded (Fig. 4A) . The broad resonances (L) arose from lipids and macromolecules, mainly methyl (L1) and methylene groups (L2 to L6) along fatty acid chains, while sharp peaks arose from small molecules, i.e., metabolites (Fig. 4, A and B) . We could detect and assign 17 metabolites ( fig. S7A ), and the main spectral contributions were due to total creatine (8) , phospholipid intermediates (9-12), taurine (14) , and myo-inositol (15) . Peaks corresponding to aliphatic chains of lipids and macromolecules were all down-regulated ( fig. S7B ). The multivariate statistical model showed a very good separation between the two mouse genotypes ( fig. S7C ), mainly due to the lower level of all acyl chain groups (L4 to L6).
These analyses also showed that the most striking changes in metabolite levels between WT and cKO groups could be ascribed to -d-glucose (17), glutamate (6), and alanine (2) . Quantification of these metabolites confirmed the statistically significant decrease in -d-glucose and increase in alanine and glutamate levels in sciatic nerves of cKO animals ( Fig. 4C) . Together, these results indicate that Lkb1 loss rewires the metabolism of a nervous tissue enriched in NCC derivatives (Fig. 4D ).
Pyruvate-alanine transamination dictates glial differentiation
We used the JoMa1.3 cells to further explore the biological effects of alanine biosynthesis during glial cell commitment in vitro. Alanine concentration in JoMa1.3 cells cultured in glial differentiation medium was increased in the absence of Lkb1 (Fig. 4E) , thus validating the in vivo observations. In addition, we confirmed the accumulation of alanine in Lkb1-null mouse embryonic fibroblasts (MEFs; fig. S7D ). Conversely, alanine was not increased in JoMa1.3 progenitor cells upon Lkb1 knockdown ( fig. S7E ).
Lkb1 has been found to control the maturation of Schwann cells at later steps of Schwann cell differentiation by regulating citrate synthase activity (26) . When citrate levels were measured in our model of early stage of glial commitment, no variation of this metabolite could be detected in the absence of Lkb1, neither in JoMa1.3 progenitors nor in glial cells ( fig. S7F ).
AMPK activation with its agonist 991 in WT MEF triggered a decrease of alanine concentration (Fig. 4F) , whereas MEF cells doubly knocked out for AMPK1/2 catalytic subunits exhibited a significant increased level of alanine (Fig. 4G) . However, inhibition of saltinducible kinases (SIK), which are activated by LKB1, with the compound HG-9-91-01 did not modify alanine levels in MEF (fig. S7, G and H). These data indicate that AMPK is a major effector downstream of LKB1 that contributes to the inhibition of alanine biosynthesis.
Our results support a mechanistic link between Lkb1 function and pyruvate-alanine transamination via the ALAT (Fig. 4H, left) , either cytoplasmic (ALAT1) or mitochondrial (ALAT2). To address this question, ALAT enzymatic activity was blocked using the inhibitor -chloro-l-alanine (chloroalanine) (Fig. 4H, right) (35) . The alanine level was normalized upon Lkb1 knockdown, thus demonstrating that chloroalanine is a genuine inhibitor of ALAT in glial JoMa1.3 cells (fig. S7I ). We also measured lactate levels and observed that Lkb1 knockdown resulted in a decrease of lactate concentration, whereas chloroalanine treatment led to an increase of lactate level ( fig. S7J) . Therefore, Lkb1 silencing induced a preferred conversion of pyruvate into alanine rather than to lactate. To examine the relation of the pyruvate/alanine transformation with glycolysis, we measured medium acidification due to the excretion of both lactate and proton using the Seahorse analyzer. The basal glycolysis and glycolytic capacity were slightly reduced, while the glycolytic reserve was markedly diminished in the absence of Lkb1 (fig. S7K ). However, upon ALAT inhibition with chloroalanine, the extracellular pH of cells with or without Lkb1 was similar, thus demonstrating that glycolysis was not affected (fig. S7L ). These data thus support the idea that the pyruvate is preferentially transformed into alanine upon Lkb1 knockdown independently of the glycolytic rate. We next evaluated the ability of cells to be specified into the glial lineage upon both Lkb1 knockdown and ALAT inhibition. Chloroalanine treatment of Lkb1-knockdown cells led to a drastic reduction of actin stress fiber formation ( fig. S7M ) and rescued expression of the glial marker S100 (Fig. 4I) .
Analyses of the expression of a set of genes coding for metabolic enzymes during glial differentiation showed that progenitor cells expressed, at a higher level, the genes coding for lactate dehydrogenase A (LDHA) and pyruvate kinase M2 (PKM2), whereas glial cells had enriched expression of lactate dehydrogenase B (fig. S7N ). LDHA and PKM2 are associated with cell proliferation (36) , and their enriched expression in progenitor cells fits with the neural crest stem phenotype of JoMa1.3 cells. However, Lkb1 knockdown did not drastically change the expression levels of these metabolic genes (Fig. 4J) . However, with a low threshold (over −0.5 or 0.5), we observed that GPT2 expression, which encodes the mitochondrial form of ALAT, was enriched in glial cells upon Lkb1 knockdown, thereby suggesting that alanine accumulation is linked to an elevated expression of GPT2.
Alanine production controls glial cell fate in an mTOR-dependent manner The LKB1-AMPK signaling pathway suppresses the function of the mTORC1, an essential regulator of protein synthesis, growth, and metabolism (37) . Consistent with this function, the phosphorylation of the S6 ribosomal protein (S6RP), a substrate of the p70S6 kinase acting downstream of mTORC1, was enhanced in the enteric ganglia of intestine and colon regions of cKO mice as well as in the sciatic nerves (Fig. 5, A and B) . We also observed an activation of the mTORC1 pathway in JoMa1.3 progenitor and glial cells upon Lkb1 knockdown (Fig. 5C ). Conversely, a substantial decrease of mTORC1 was detected upon chloroalanine treatment (Fig. 5D) , suggesting that this kinase acts downstream of the pyruvate-alanine pathway.
To evaluate the connection between alanine levels, mTORC1 activity, and glial differentiation, we cultivated JoMa1.3 cells in glial differentiation conditions with increasing doses of alanine. We first validated that alanine accumulated in glial cells ( fig. S8A ). In these conditions, mTOR activity was up-regulated ( fig. S8B ) and glial differentiation was impaired ( fig. S8C) , thus recapitulating the effects of Lkb1 knockdown in glial cells. To explore if alanine levels are essential to maintain stemness, we treated JoMa1.3 progenitor cells with the ALAT inhibitor chloroalanine. This treatment decreased basal levels of alanine ( fig. S8D) and limited mTORC1 activity (fig. S8E) . However, ALAT inhibition in progenitors did not trigger any "by default" glial differentiation ( fig. S8F ). Together, these data highlight the interconnected regulation of alanine biosynthesis and mTORC1 activity and demonstrate that alanine levels are essential for glial differentiation.
Because our data hinted at a mechanistic link between the sensing of alanine levels and mTOR activity, we treated Lkb1 knockdown JoMa1.3 cells with the mTOR inhibitor Torin1. As expected, Torin1 normalized mTOR activation in JoMa1.3 cells silenced for Lkb1 (Fig. 5E ). Immunofluorescence staining with the glial marker S100 revealed that Torin1 treatment rescued glial differentiation of Lkb1-deficient cells (Fig. 5F ). These data provide evidence that Lkb1 controls glial cell differentiation through the regulation of alanine synthesis that acts upstream of mTOR.
Reduced mitochondrial respiration does not affect glial differentiation
LKB1 and AMPK play a crucial role in controlling mitochondrial activity (25, 26, (38) (39) (40) . Therefore, we assessed whether the inhibition of glial differentiation caused by Lkb1 inactivation was associated with mitochondrial defects. After labeling cells with MitoTracker, a vital stain that accumulates in active mitochondria, mitochondria of cKO sciatic nerves appeared more dispersed in myelinated fibers compared to WT littermates (Fig. 6A) . Electron microscopy showed dilated mitochondrial cristae in the absence of Lkb1 (Fig. 6B) . Using MitoTracker staining and flow cytometry analyses in JoMa1.3 cells, a significant increase of the mitochondrial mass was observed (Fig. 6C) . Confocal microscopy analyses revealed a marked reorganization of the mitochondria network that acquired a large circular morphology (Fig. 6D) . Next, we assessed the respiratory capacities of Lkb1-deficient glial JoMa1.3 cells and found a significant diminution of oxygen consumption during basal, maximal, and spare respiration. Adenosine 5´-triphosphate (ATP) production was also significantly reduced (Fig. 6E) . However, chloroalanine treatment did not rescue the mitochondrial respiration (Fig. 6F) , thus indicating that reduced oxygen consumption in our system is not linked to the inhibition of glial differentiation.
AICAR rescues glial differentiation and prevents in vivo NCC defects
The AICAR compound is phosphorylated by adenosine kinase inside the cells and is converted to purine nucleotides, among them 5-aminoimidazole-4-carboxamide ribotide (AICA ribotide or ZMP) and AMP, two allosteric activators of AMPK (41) . Although AICAR has been described as an AMPK agonist in the presence of Lkb1, there is increasing evidence that this molecule exerts AMPK-independent metabolic effects (42) (43) (44) . Furthermore, AICAR supplementation promotes astroglial differentiation independently of AMPK (44) . These data prompted us to test whether AICAR could rescue glial differentiation of Lkb1-deficient NCC derivatives. AICAR treatment decreased actin stress fiber formation ( fig. S9A ) and rescued S100 expression (Fig. 7A) . AICAR had no effect on alanine levels (fig. S9B) ; however, it significantly diminished mTORC1 activation without restoring AMPK phosphorylation (Fig. 7B) . Notably, AICAR treatment affected neither mitochondrial respiration ( fig. S9C ) nor glycolysis ( fig. S9D) . Together, these findings suggest that AICAR rescued Lkb1 loss by acting downstream of alanine biosynthesis and upstream of mTORC1.
We next explored the in vivo effects of AICAR on Lkb1 cKO mice. Lkb1-deficient mice were treated by intraperitoneal injections of AICAR (0.5 mg/g body weight) every 2 days from P10 to P18. We first observed that weight loss of cKO animals was reduced upon AICAR infusion (Fig. 7C) . Furthermore, at P21, mutant mice treated with AICAR displayed increased mobility and ameliorated leg reflex extension when lifted by their tail compared to mutant mice treated with vehicle (Fig. 7D) . In addition, P21 mutant mice showed less intestinal dilation (Fig. 7E) . As observed in vitro, AICAR also limited in vivo mTOR up-regulation due to Lkb1 loss. Inhibition of mTORC1 signaling was restored both in sciatic nerves (Fig. 7F ) and in the enteric nervous system (Fig. 7G) . Strikingly, neuronal and glial enteric cells were maintained in mutant mice with AICAR (Fig. 7H) . Thus, AICAR rescued, at least in part, enteric and Schwann cell defects of cKO mice.
DISCUSSION
Multipotent NCCs face a limiting supply of oxygen and nutrients during their journey through the embryo and the distant colonization of organs. The metabolic adaptation of NCC to these microenvironmental conditions constrains their migration, proliferation, differentiation, and survival. However, the metabolic pathways that are involved in the formation of neural crest derivatives have remained poorly characterized. We show here that the tumor suppressor kinase LKB1 is a key effector in an NCC metabolic program that drives melanocyte and glial cell differentiation.
Disruption of Lkb1 in the subpopulation of NCC expressing tyrosinase impaired the differentiation of melanocytes, enteric ganglion cells, and Schwann cells. It has been previously reported that the combined inactivation of Lkb1 and the oncogenic activation of K-Ras in melanocytes led to inappropriate melanogenesis and to the metastatic expansion of melanoma (45) . We now establish that Lkb1 is required during the first wave of melanocytic differentiation. In addition, we found that Lkb1 activity is also necessary for the postnatal maintenance of neurons and glial cells of myenteric and submucosal plexi. However, we cannot exclude that Lkb1 also functions at earlier stages of vagal NCC migration, because NCCs invade the rostral foregut at E8.5 or E9, while the tyrosinase promoter is turned on at E10.5. Unexpectedly, we did not detect an increase of NCC apoptosis that might account for the defect in the enteric nervous system. However, apoptosis may occur at earlier stages of NCC development and went undetected in our experiments. Alternatively, an unconventional death of postmigratory enteric neurons has been described in mice with a conditional ablation of each subunit of the glial cell line-derived neurotrophic factor (GDNF) receptor, GFR1 and RET (46, 47) . It might thus be interesting to explore if Lkb1 loss affects GDNF signaling. Strikingly, Schwann cell precursors (SCPs) depend on GDNF signaling to populate the gut through extrinsic nerves (48, 49) . SCPs are progenitors from peripheral nerves with NCC stem-like properties that contribute to the postnatal integrity of the enteric nervous system (50) . It is thus plausible that postnatal degeneration of the enteric nervous system occurring in Lkb1 cKO mice reflects an attrition of the SCP pool.
Our work further revealed that NCC-specific ablation of Lkb1 resulted in a progressive peripheral neuropathy stemming from an impaired differentiation of Schwann cells. These results are consistent with recent studies demonstrating the implication of Lkb1 in Schwann cell axon maintenance and myelination using Cnp::Cre or P0::Cre drivers (25) (26) (27) . Despite the fact that our Lkb1 mutant mice displayed phenotypic manifestations at earlier developmental stages (around 2 to 4 weeks after birth), we observed a similar disruption of Schwann cell polarization and mitochondrial activity. However, in contrast with a previous report (26), we found that mitochondrial respiration is not required for glial cell commitment. This discrepancy probably reflects that, in our conditions, early stages of the glial lineage were studied when the cells are still actively proliferating. Along this line of thinking, the timing of Lkb1 inactivation likely explains why we did not observe a decrease of the level of the citrate metabolite, as previously reported in Schwann cells that lack Lkb1 (26) . By combining in vivo, metabolomics, and pharmacological approaches, we found instead that Lkb1 deletion led to an intracellular accumulation of alanine. Inhibition of pyruvate-alanine transamination restored glial differentiation of Lkb1-deficient NCC, whereas treatment of NCCs with alanine blocked their glial differentiation. We further established that AMPK is a key negative regulator of alanine biosynthesis downstream of Lkb1 ( fig. S10) . It has been recently demonstrated that rapidly proliferating mammary epithelial cells use transaminases to link nonessential amino acids synthesis to the production of -ketoglutarate and tricarboxylic acid anaplerosis (51) . Furthermore, the activation of GPT2 expression, the gene encoding ALAT2, is required to maintain the malignant phenotype of colon cells by coupling of glycolytic flux to anaplerosis (52) . These findings are in agreement with our data because the unchecked activation of the pyruvate-alanine cycling is incompatible with the transition of Lkb1-deficient NCC to quiescence and subsequent glial differentiation. Lkb1 loss has also been associated with an increased expression of phosphoserine amino transferase, an enzyme participating to the serine-glycine one-carbon network whose aberrant activation supports the malignant transformation of Lkb1-mutant pancreatic cells (53) . These data point to Lkb1 as a key actor of a metabolic checkpoint that controls a switch between cell proliferation and differentiation through transaminasesdependent alanine synthesis.
We report here that mTORC1 activation is connected to the elevated alanine level and that inactivation of mTOR signaling restored glial differentiation of Lkb1-deficient NCC. mTORC1 is known to control cranial NCCs (54, 55) and early and late stages of Schwann cell differentiation, and an adequate dosage of mTOR activity is required for the peripheral nervous system myelination (56) (57) (58) (59) (60) . In addition, in agreement with our results, mTORC1 reactivation has been associated with Schwann cell dedifferentiation during nerve injury (61). Although we have explored the link between alanine and mTORC1 in glial differentiation, we cannot rule out the involvement of mTORC2 in this process. mTORC1 is stimulated in response to the sensing of amino acids in particular leucine and arginine (62) . However, additional amino acids are presumably involved in this process (63, 64) . In support of this notion, it has been recently demonstrated that mTORC1 is activated in two consecutive priming and activation steps (65) and that alanine belongs to the group of priming amino acids. These findings suggest a rational mechanistic explanation supporting our data, and it will thus be relevant to investigate how alanine sensing might be tied to the activation of mTORC1.
In this context, it was an unexpected observation that the treatment of Lkb1-deficient NCC with the cell-permeable nucleoside AICAR normalized mTORC1 signaling both in vitro and in vivo without restoring AMPK phosphorylation and promoted glial differentiation in vitro. AICAR is mostly known to exert its biological effects through AMPK, although it has become progressively evident that this metabolite has additional cellular targets (66) . Recent reports showed that AICAR acts in an AMPK-independent manner either on mTOR inhibition or on the Nrf2 pathway (67, 68) . The remarkable rescue of hind limb paralysis and enteric nervous system degeneration obtained with AICAR indicates that this compound or molecules up-regulating its intracellular level (69) may represent a viable therapeutic intervention to target the metabolic defects induced by LKB1 inactivation.
Collectively, this study and our previous report (18) identify the LKB1 pathway as a central orchestrator of neural crest development and highlight the pivotal role of energy metabolism in the formation of NCC lineages. These findings also raise the idea that a dysfunctional LKB1 signaling network could underlie the metabolic etiology of human neurocristopathies including peripheral neuropathies and intestinal motility disorders.
METHODS

Animals and genotyping
Floxed Lkb1 mice were obtained from R. A. DePinho (Boston, USA), and R26R mice were provided by P. Soriano ;Tyr::Cre male mice). Embryos and mice were genotyped by multiplex polymerase chain reaction (PCR) using DNA extracted from tails with primers indicated in Table 1 and PCR conditions in original references cited previously. For timed pregnancies, mice were bred and the time of plug identification was counted as day 0.5. Mice were maintained under standard housing conditions at the animal facility Plateforme Haute Technologie Animalerie (PHTA) of Grenoble and on a mixed genetic background. Tyr::Cre +/tg ;Z/EG +/tg mice were described previously (28, 70) . All animal experimental procedures were conducted according to the standard operating procedures of the laboratory animal facility and were approved by the Animal Ethics Committee of Grenoble (permit no. 261_ IAB-U823-CT-01).
Human samples
Normal human intestine and colon tissue samples were obtained from biopsies of patients with peritoneal intestinal carcinosis. All samples collected were taken at distance from the bulk of the tumor, stored, and used with the informed consent from the patients.
Cell culture conditions, siRNA transfection, and metabolic drug treatments Lkb1 null mouse immortalized embryonic fibroblasts or reconstituted to express Lkb1 were cultivated as previously described (71) . Culture of mouse immortalized embryonic fibroblasts WT or double knockout for AMPK1/2 was performed as previously described (72) .
Mouse immortalized neural crest stem cells (JoMa1.3) were cultured on fibronectin (10 g/ml; 1 hour at 37°C)-coated surfaces following the protocol described by Maurer et al. (34) . Differentiation of these cells into glial cells was achieved by coating surfaces with poly-l-lysine (10 g/ml; 1 hour at 37°C) and fibronectin and by adding heregulin (50 ng/ml; PeproTech,120-02) and forskolin (5 M; Sigma) to the culture medium for 6 days. The medium was replaced every 2 days.
siRNAs against the mouse Lkb1 gene and the nontargeting control siRNA were purchased from Dharmacon (ON-TARGETplus Mouse Stk11 SMART Pool and ON-TARGETplus Non-targeting Pool). siRNAs were first transfected (60 nM) into JoMa1.3 progenitor cells (2 × 10 4 cells/ml) by using jetPRIME (Ozyme) according to the manufacturer's protocol. For nondifferentiated JoMa1.3 cells, experiments were performed 72 hours after transfection. For differentiated JoMa1.3 cells, 3 days after the first transfection, cells were redistributed (2 × 10 4 JoMa1.3 cells/ml) and transfected again 48 hours later. Thus, two cycles of 96 hours of Lkb1 knockdown were performed, as described in fig. S4E .
During the 6 days of cell differentiation and the second cycle of Lkb1 inactivation, cells were cultivated in NCC medium and replaced every 2 days from days 4 to 9 and supplemented when indicated with different metabolic inhibitors: 100 M chloroalanine (ALAT inhibitor; Sigma), 10 nM Torin1 (an mTOR inhibitor; Euromedex), and 50 M AICAR (a metabolic regulator and AMPK agonist; Millipore).
For alanine supplementation experiments, JoMa1.3 cells (seeded at 2 × 10 4 cells/ml) were supplemented with alanine during 4 or 5 days in glial differentiation medium and replaced every 2 days. When indicated, cells were treated with Torin and AICAR as described above.
Electron microscopy
For electron microscopy, mice were anesthetized with ketamine/xylazine and perfused with 2% paraformaldehyde and 0.2% glutaraldehyde in phosphate-buffered saline (PBS) (0.1 M, pH 7.4), and dissected sciatic nerves were fixed with 2% paraformaldehyde and 2.5% glutaraldehyde in PBS (0.1 M, pH 7.4) for 1 hour at room temperature and post-fixed in 1% osmium tetroxide in cacodylate buffer (0.1 M, pH 7.2) for 1 hour at 4°C. After washing, tissues were stained in 0.5% uranile acetate (pH 4) for 1 hour at 4°C, then dehydrated through graded alcohols, and embedded in Epon. Semithin sections (500 nm) were stained with toluidine blue before being observed with an optical microscope. Ultrathin sections (50 nm) were analyzed with a transmission electron microscope (JEOL 1200EX, Grenoble Institute of Neurosciences, France) at 80 kV, and images were acquired using a digital camera (Veleta, Olympus). Morphometric measurements were done with ITEM software (Soft Imaging System, Olympus). The same protocol was applied for electron microscopy on JoMa1.3 cells.
Teased fiber preparation and staining
Sciatic nerves were isolated from WT or cKO mice, teased on glass slides, fixed for 30 min in 4% paraformaldehyde, and subsequently washed in PBS (73) . After teasing, the nerves were dried overnight at room temperature and stored at −20°C. For E-cadherin immunostaining, the teased fibers were permeabilized in cold acetone for 10 min, washed with PBS, incubated for 1 hour at room temperature in blocking solution (10% goat serum and 0.3% Triton X-100 in PBS), and then incubated with primary antibodies in blocking solution overnight at 4°C. Samples were washed in PBS and incubated for 1 hour at room temperature with secondary antibodies. Last, samples were washed in PBS incubated in Hoechst to stain nuclei and mounted in Mowiol. Images were acquired using a Zeiss Biphoton confocal microscope (LSM510).
To label mitochondria, teased fibers were incubated with MitoTracker Red CMX-ROS (Invitrogen) for 30 min at 37°C (500 nM), washed in PBS, fixed for 10 min in 4% paraformaldehyde, incubated in Hoechst for 10 min, and mounted in Mowiol. Images were acquired using a Zeiss Biphoton confocal microscope (LSM510).
Seahorse analyses
The extracellular acidification rate (ECAR) and O 2 consumption rate (OCR) were analyzed using the Seahorse XF-Analyzer (Seahorse Bioscience), and 3 × 10 4 cells were seeded in 96-well Seahorse plates in glial JoMa1.3 culture medium for 16 hours before assay. Cells were equilibrated with DMEM lacking bicarbonate at 37°C for 1 hour in a custom incubator without CO 2 . OCR and ECAR were measured at baseline following addition of reagents for indicated times. For the mitochondrial respiration, the spare respiratory capacity was calculated by subtracting the maximal respiration values by the basal respiration values. For both respiration and glycolysis, quantifications were performed by calculating for each category the mean and SD from the values obtained from several independent experiments.
Biochemical dosages
Metabolites were quantified from 10 7 JoMa1.3 cells using the Alanine Assay Kit (BioVision, K652-100), Citrate Assay Kit (BioVision, K655-100), and Lactate Assay Kit (BioVision, K2092-100) according to the manufacturer's protocols.
AICAR treatment of mice
WT and cKO mice were treated with AICAR (0.5 mg/g body weight) or vehicle by intraperitoneal injection (100 l per mouse) every 2 or 3 days from P10 to P18. Mice received five injections and were sacrificed at P21 and analyzed as described previously.
Graphical representations and statistical analyses
All cell culture experiments were realized at least by three independent experiments, and for one experiment, each condition was performed in triplicate. In vivo analyses were conducted with at least three animals per condition. The exact number of experiments is indicated in the figures or in the legends. Values are given as mean with SD. Normality of the data was checked with the F test. The unpaired Student's t test was used to generate P values for selected pairwise comparisons, and P < 0.05 was considered significant.
Nerve metabolomic profiling by HRMAS NMR
Sciatic nerves from 16 WT mice and 13 cKO animals were rapidly dissected at p21, cleaned of surrounding fat and connective tissues, and immediately frozen in liquid nitrogen. Left and right nerves of each animal were inserted in a disposable insert for HRMAS NMR spectroscopy in a −20°C cooling chamber. was added to the sample in the disposable insert, which was sealed and inserted in a 80-l zirconium rotor. 1 H NMR spectra were acquired with a Bruker Avance III 500 spectrometer (Bruker BioSpin, Wissembourg, France) (CEA-Grenoble and IRMaGe facility). Samples were spun at 4000 Hz, and temperature was maintained at 4°C for all experiments. One-dimensional spectra were acquired with a Carr-Purcell-Meiboom-Gill pulse sequence synchronized with the spinning rate (interpulse delay, 250 s; total spin echo time, 30 ms). The acquisition of one 1 H NMR spectrum consisted of 512 scans lasting 32 min. Residual water signal was presaturated during the 1.5-s relaxation delay time.
Sample preparation for HRMAS NMR
H HRMAS NMR acquisition
Spectra preprocessing
All preprocessing steps were performed using the TopSpin 3.1 Bruker software (Bruker BioSpin, Karlsruhe, Germany). Spectra were aligned to the TSP signal at 0 ppm and phase-corrected. A five-order polynomial was systematically applied for baseline correction.
All spectra from 4.678 to 0.60 ppm were divided into intervals or buckets equal to 10 −3 ppm using the AMIX software (Bruker). Each bucket was normalized to total spectrum amplitude. Because this procedure can mask minor peak variations when very intense peaks are present in the spectra, e.g., lipid peaks (L2 peak; Fig. 4A ), we also performed bucketing on a reduced spectral region starting from 1.825 ppm (Fig. 4A, into brackets) . Resonance assignment was performed as previously described [for metabolites: (74, 75) ; for lipids: (76, 77) ].
Multivariate statistical analysis
Buckets were then imported into SIMCA v13 software (Umetrics AB, Umea, Sweden) for multivariate statistical analysis. Buckets were mean-centered, scaled to unit variance (i.e., weighted by 1/SD for a given variable), and submitted to a principal components analysis (PCA) to ensure good homogeneity of data and possibly to exclude outliers. For this aim, data were visualized by score plots, where each point represents an NMR spectrum and thus a sample. Supervised analyses like orthogonal partial least square discriminatory analyses (OPLS-DA) were thus performed using the group belonging (control or exposed) as Y matrix. The number of components was determined using the cross-validation procedure that produces R 2 Y and Q 2 factors (>0.5). Moreover, the reliability of our OPLS-DA model was assessed by a CV-ANOVA (cross-validated analysis of variance) test. The results were visualized by plotting the score of individuals relative to the first two components of the model. To highlight metabolites that are the most discriminating between controls and exposed, S-line was examined. This plot allows the visualization in a single graph, which mimics an NMR spectrum, the covariance (peak intensity), and correlation (peak color) between cKO and WT animals. Moreover, the signs of peaks in S-line give indications about the direction of change of metabolites-increased (positive peaks) or decreased (negative peaks) relative to WT.
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